Sandoz Gains Rights To Two US Injectables
Further Signal Of Intent For US Sterile Injectables Strategy
With the $1bn deal to transfer its US dermatology and orals solids operations to Aurobindo still awaiting completion, Sandoz is expanding its portfolio of sterile injectables - a key area of focus for the company - by acquiring the rights to two products from BE Pharmaceuticals.
You may also be interested in...
Overcoming residual negative perceptions around generics, reforming Medicaid and Medicare policies that unfairly penalize generics and ensuring that “skinny label” generics can continue to be marketed are among the key priorities for Sandoz in the US, Carol Lynch, president of Sandoz Inc. and head of North America, tells Generics Bulletin in an exclusive interview.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.